MX2014009845A - Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. - Google Patents

Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.

Info

Publication number
MX2014009845A
MX2014009845A MX2014009845A MX2014009845A MX2014009845A MX 2014009845 A MX2014009845 A MX 2014009845A MX 2014009845 A MX2014009845 A MX 2014009845A MX 2014009845 A MX2014009845 A MX 2014009845A MX 2014009845 A MX2014009845 A MX 2014009845A
Authority
MX
Mexico
Prior art keywords
rabies
proteins
polypeptide
made therefrom
vectors expressing
Prior art date
Application number
MX2014009845A
Other languages
English (en)
Other versions
MX360415B (es
Inventor
Jules Maarten Minke
Teshome Mebatsion
Frederic David
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MX2014009845A publication Critical patent/MX2014009845A/es
Publication of MX360415B publication Critical patent/MX360415B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8633—Avian poxviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona vectores que contienen y co-expresan polipéptidos o antígenos inmunogénicos in vivo o in vitro junto con un polipéptido 0X40L, que funciona como un adyuvante genético. Conjuntamente, el polipéptido inmunogénico y el polipéptido 0X40L inducen una respuesta inmune en el animal o humano, que es mayor que la respuesta inmune inducida por el polipéptido inmunogénico solo. En un ejemplo particular, la invención proporciona vectores que codifican un polipéptido inmunogénico G de Rabia y un adyuvante genético 0X40L canino, los vectores que inducen fuertes respuestas inmunes en el canino contra el virus de rabia.
MX2014009845A 2012-02-14 2013-02-14 Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. MX360415B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598610P 2012-02-14 2012-02-14
PCT/US2013/026206 WO2013123242A1 (en) 2012-02-14 2013-02-14 Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom

Publications (2)

Publication Number Publication Date
MX2014009845A true MX2014009845A (es) 2015-03-10
MX360415B MX360415B (es) 2018-10-31

Family

ID=47757705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009845A MX360415B (es) 2012-02-14 2013-02-14 Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.

Country Status (13)

Country Link
US (2) US9567606B2 (es)
EP (2) EP2814506B1 (es)
JP (1) JP6260972B2 (es)
CN (1) CN104203271B (es)
AU (1) AU2013221502C1 (es)
BR (1) BR112014020019A8 (es)
CA (1) CA2864119C (es)
EA (1) EA032389B1 (es)
ES (2) ES2723273T3 (es)
HK (1) HK1200327A1 (es)
MX (1) MX360415B (es)
NZ (2) NZ628270A (es)
WO (1) WO2013123242A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
JP6260972B2 (ja) 2012-02-14 2018-01-17 メリアル インコーポレイテッド 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン
MX2015010880A (es) 2013-02-22 2015-12-03 Curevac Gmbh Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
US10196435B2 (en) * 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
EP3083947B1 (en) * 2013-12-20 2019-04-03 Boehringer Ingelheim Vetmedica GmbH Prrs virus variant, european prrs virus cdna clone, and uses thereof
CN103877570B (zh) * 2014-02-19 2016-01-20 北京中联康生物科技有限公司 狂犬病活疫苗和制备狂犬病口服活疫苗的方法
WO2015135558A1 (en) * 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
EP3215188A1 (en) * 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
CA3024917A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JP2021514196A (ja) 2018-02-23 2021-06-10 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 外因性ネコパラミクソウイルス遺伝子を発現する組換えウイルスベクター系およびそれらから製作されるワクチン
CN111518776A (zh) * 2020-04-16 2020-08-11 大理大学 一种重组狂犬病病毒疫苗株及其制备方法
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
US11149286B1 (en) * 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
WO2023152486A1 (en) * 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
CN116656730B (zh) * 2023-05-25 2024-03-19 军事科学院军事医学研究院军事兽医研究所 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US6309647B1 (en) * 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
FR2724385B1 (fr) 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
WO2002036170A2 (en) * 2000-11-03 2002-05-10 Oxford Biomedica (Uk) Limited Vector system for transducing the positive neurons
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7582302B2 (en) 2004-06-04 2009-09-01 Merial Limited Needle-free administration of FeLV vaccines
EP1773387B1 (en) 2004-06-25 2013-06-12 Merial Ltd. Avipox recombinants expressing foot and mouth disease virus genes
US8980280B2 (en) 2005-03-30 2015-03-17 Merial, Inc. Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
PL1881845T3 (pl) 2005-04-25 2010-08-31 Merial Ltd Szczepionki przeciwko wirusowi Nipah
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8008268B2 (en) 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
US7910112B2 (en) 2006-11-06 2011-03-22 Merial Limited Feline vaccines against avian influenza
EP2086580A2 (en) 2006-11-21 2009-08-12 Merial Limited Prime boost canine leishmania vaccine
PL2358742T3 (pl) 2008-10-24 2018-08-31 Merial, Inc. Szczepionka przeciwko wirusowi afrykańskiego pomoru koni
CN101884793A (zh) 2010-06-29 2010-11-17 中国人民解放军第三军医大学 乙肝病毒核心抗原的免疫增强型基因疫苗及其制备方法
JP6260972B2 (ja) 2012-02-14 2018-01-17 メリアル インコーポレイテッド 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン

Also Published As

Publication number Publication date
ES2866108T3 (es) 2021-10-19
BR112014020019A8 (pt) 2022-07-12
US20170137843A1 (en) 2017-05-18
JP6260972B2 (ja) 2018-01-17
AU2013221502C1 (en) 2018-03-01
US10006050B2 (en) 2018-06-26
AU2013221502A1 (en) 2014-08-28
EA032389B1 (ru) 2019-05-31
AU2013221502B2 (en) 2017-10-26
US20130209511A1 (en) 2013-08-15
EP2814506A1 (en) 2014-12-24
ES2723273T3 (es) 2019-08-23
HK1200327A1 (en) 2015-08-07
BR112014020019A2 (pt) 2017-07-04
MX360415B (es) 2018-10-31
CN104203271B (zh) 2017-08-25
EP3466443B1 (en) 2020-12-16
CA2864119A1 (en) 2013-08-22
NZ722700A (en) 2017-12-22
EP2814506B1 (en) 2018-11-28
EA201400912A1 (ru) 2015-01-30
JP2015511948A (ja) 2015-04-23
CA2864119C (en) 2022-05-24
EP3466443A1 (en) 2019-04-10
US9567606B2 (en) 2017-02-14
NZ628270A (en) 2016-09-30
CN104203271A (zh) 2014-12-10
WO2013123242A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
MX360415B (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
PH12015502790A1 (en) Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
MX2017011322A (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
MX363149B (es) Vacunas de nucleoproteina de la influenza.
WO2012115715A3 (en) Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX2019007924A (es) Vacunas contra la influenza.
MX351642B (es) Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX2010008170A (es) Vacunas para influenza canina.
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
WO2011133870A3 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERIAL, INC.

FG Grant or registration